Cetuximab (EGFR inhibitor)

DRUG4 trials

Conditions

Advanced Solid TumorCRCColorectal CancerHead and Neck Squamous Cell CarcinomaMetastatic Colorectal Cancer (CRC)Metastatic Head and Neck Squamous Cell CarcinomaNSCLCRadiotracer

Phase 1

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

CompletedNCT05002270

Jacobio Pharmaceuticals Co., Ltd.Advanced Solid Tumor, CRC, NSCLC

Start: 2021-09-03End: 2025-02-12Updated: 2026-01-13

Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

RecruitingNCT07217028

Vanderbilt-Ingram Cancer CenterHead and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Radiotracer +1

Start: 2026-04-24End: 2030-09-01Target: 25Updated: 2026-05-11

Phase 2

FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)

Not yet recruitingNCT07621497

Sun Yat-sen UniversityMetastatic Colorectal Cancer (CRC)

Start: 2026-06-01End: 2030-06-01Target: 229Updated: 2026-06-02

Phase 4

Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status

Not yet recruitingNCT07094893

Gruppo Oncologico del Nord-OvestColorectal Cancer

Start: 2026-04-15End: 2030-03-31Target: 280Updated: 2026-01-14

Related Papers

Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials.

2025-10-026 citations

Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors.